LPAR1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Bms-986020 (SCHEMBL14590)	1.00	20/20
SCHEMBL2073	0.63	20/20
SCHEMBL7068	0.61	20/20
SCHEMBL7710	0.61	20/20
SCHEMBL14813	0.56	20/20
SCHEMBL4130	0.53	20/20
SCHEMBL6507	0.61	19/20
SCHEMBL7069	0.61	19/20
SCHEMBL7711	0.61	19/20
SCHEMBL7454	0.60	19/20
SCHEMBL6432	0.58	19/20
SCHEMBL10707	0.57	19/20
SCHEMBL14675	0.57	19/20
SCHEMBL9958	0.52	19/20
SCHEMBL9995	0.52	19/20
SCHEMBL9996	0.52	19/20
SCHEMBL8005	0.82	18/20
SCHEMBL8006	0.82	18/20
SCHEMBL6243	0.65	18/20
SCHEMBL4142	0.58	18/20

Clinical trials — most relevant to LPAR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis	PHASE4	COMPLETED
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)	PHASE4	UNKNOWN
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite	PHASE2/PHASE3	WITHDRAWN
Montelukast in Parkinson Disease	PHASE2/PHASE3	RECRUITING
Fish Oil and Aspirin With Type 2 Diabetes	PHASE2	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Repurposing Siponimod for Alzheimer's Disease	PHASE2	RECRUITING
Assessment of Coronary Plaque Composition	PHASE1	COMPLETED
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study	PHASE1	UNKNOWN
Autotaxin (ATX) as a Marker for Breast Cancer	nan	UNKNOWN
The dıagnostıc Value of Serum autotaxın Level ın Colorectal Cancer	nan	COMPLETED
Longitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease	nan	RECRUITING
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness	nan	UNKNOWN
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study	nan	UNKNOWN
Evaluation of Cascade Screening for Elevated Lipoprotein(a)	nan	ACTIVE_NOT_RECRUITING
Positron Emission Tomography (PET) to Study Brain Signaling	nan	COMPLETED
In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme	nan	NOT_YET_RECRUITING
Clinical Study Evaluating the Effect of Losartan	nan	RECRUITING
Dose-response Effect of Pine Nut Oil as a Dual FFA1 and FFA4 Agonist on Glucose Tolerance in Healthy Humans.	nan	COMPLETED
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity	nan	NOT_YET_RECRUITING
LDL-Apheresis for FSGS CardioRenal Outcomes	nan	COMPLETED
Multi-Analyte, Genetic, and Thrombogenic Markers of Atherosclerosis	nan	UNKNOWN
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies	nan	UNKNOWN
Effect of Dietary Oils as G-protein-coupled Receptor Agonists on Glucose Tolerance	nan	UNKNOWN
FFAR Agonist on Incretins, Insulin, Lipids and Inflammation	nan	COMPLETED
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma	nan	SUSPENDED

Related proteins — ESM-2 sequence neighbours (a LPAR1 binder may also engage these)

Protein	Name	Similarity
Q9PU17	—	1.000	Q9PU17 →
Q28031	—	1.000	Q28031 →
P61794	—	1.000	P61794 →
P61793	—	1.000	P61793 →
Q9PU16	—	1.000	Q9PU16 →
P46628	—	0.997	P46628 →
Q9EQ31	—	0.995	Q9EQ31 →
LPAR3	Lysophosphatidic acid receptor 3	0.995	landscape →
Q8K5E0	—	0.994	Q8K5E0 →
Q9JL06	—	0.981	Q9JL06 →
Q9I8K8	—	0.981	Q9I8K8 →
Q61121	—	0.981	Q61121 →
A0A678XMK4	—	0.980	A0A678XMK4 →
P70585	—	0.980	P70585 →
GPR52	G-protein coupled receptor 52	0.979	landscape →
Q15760	—	0.979	Q15760 →
P34974	—	0.978	P34974 →
P0C5J4	—	0.978	P0C5J4 →
O97504	—	0.978	O97504 →
A6QLE7	—	0.978	A6QLE7 →
P18901	—	0.977	P18901 →
Q8BZ39	—	0.977	Q8BZ39 →
O70528	—	0.977	O70528 →
HTR2C	5-hydroxytryptamine receptor 2C	0.977	landscape →
P70596	—	0.977	P70596 →
HTR4	5-hydroxytryptamine receptor 4	0.976	landscape →
MC4R	Melanocortin receptor 4	0.976	landscape →
Q8HXX3	—	0.976	Q8HXX3 →
Q9NDM2	—	0.976	Q9NDM2 →
MC5R	Melanocortin receptor 5	0.976	landscape →